Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Japan Pharmaceuticals And Healthcare Industry
SWOT — 6
Japan Political SWOT — 7
Japan Economic SWOT — 7
Pharmaceutical Business
Environment Ratings — 8
Limits Of Potential
Returns — 9
Risks To Realisation Of
Returns — 9
Market Summary — 11
Regulatory Regime — 12
Recent Regulatory
Developments — 13
Intellectual Property
Developments — 14
Pricing And Reimbursement
System — 15
Table: Reimbursement Categories And
Rates — 16
Recent Pricing And Reimbursement
Developments — 16
The Federation Of Pharmaceutical
Manufacturers Association Of Japan (FPMAJ)’s Proposed Revisions To The
National Health Insurance
Pricing Procedures — Error!
Bookmark not defined.
Other Regulatory Issues — 19
Table: Concerns Of Pharmaceutical Associations — 20
International Trade Agreements — 20
Industry Trends and
Developments — 22
Epidemiology — 22
Healthcare Sector — 25
Healthcare Sector
Financing — 25
Healthcare Reforms — 26
International Reaction — 27
Pharmaceutical
Industry — Error! Bookmark not defined.
Domestic Company
Activity — Error! Bookmark not defined.
Foreign Generic
Sector — 27
Multinational Sector
Developments — 29
Key developments in recent years include
the following: — 29
Pharmaceutical Wholesale and
Retail — 31
Research And
Development — 32
Medical Devices — 32
Medical Device Regulations — 33
Industry Forecast
Scenario — 34
Overall Market
Forecast — 34
Table: Japan – Drug Market Indicators,
2005-2013 — 35
Key Growth Factors –
Industry — 36
Table: Japan – Healthcare Market
Indicators, 2005-2013 — 37
Macroeconomic Forecast
Scenario — 38
Table: Japan – Macroeconomic
Forecasts, 2008-2012 — 42
Prescription Drug Market
Forecast — 43
Table: Japan – Prescription Drug
Market Indicators, 2002-2013 (JPYmn unless otherwise
stated) — 44
OTC Medicine Market
Forecast — 46
Table: Japan – OTC Market Indicators,
2005-2013 (JPYmn unless otherwise stated) — 49
Patented
Product Market Forecast — 50
Table: Japan – Patented
Medicines Market Indicator, 2005-2013 (JPYmn unless otherwise
stated) — 51
Generic Drug Market
Forecast — 52
Table: Japan – Generic Drug Market
Indicators, 2002-2013 (JPYmn unless otherwise stated) — 53
Pharmaceutical Trade Forecast — 54
Table: Japan –
Pharmaceutical Export/Import Indicators, 2002-2013
(US$mn) — 55
Other Healthcare Data And
Forecasts — 55
Table: Japan – Other Healthcare
System Indicators, 2002-2013 — 56
Key Risks To BMI’s
Forecast Scenario — 56
Competitive
Landscape — 57
Company Profiles — 58
Leading Foreign Manufacturers — 58
Pfizer — 58
Sanofi-Aventis — 61
Merck
& Co (Banyu) — 63
Novartis — 66
GlaxoSmithKline (GSK) — 69
AstraZeneca — 71
Indigenous
Manufacturers — 73
Takeda — 73
Astellas — 77
Eisai — 81
Daiichi
Sankyo — 85
Mitsubishi Tanabe — 88
Sawai Pharmaceutical — 90
Country Snapshot: Japan
Demographic Data — 92
Section 1:
Population — 92
Table: Demographic Indicators,
2005-2030 — 92
Table: Rural/Urban Breakdown,
2005-2030 — 93
Section 2: Education And
Healthcare — 93
Table: Education,
2002-2005 — 93
Table: Vital Statistics,
2005-2030 — 93
Section 3: Labour Market And Spending
Power — 94
Table: Employment Indicators,
2001-2006 — 94
Table: Consumer Expenditure, 2000-2012
(US$) — 95
Table: Average Annual Wages,
2000-2012 — 95
BMI Forecast
Modelling — 96
How We Generate Our Pharmaceutical Industry
Forecasts — 96
Pharmaceutical Business Environment Ratings
Methodology — 97
Ratings Overview — 97
Table: Pharmaceutical Business Environment Indicators — 98
Weighting — 99
Table: Weighting Of
Components — 99
Sources — 99
| 
View Cart
